Record profits for Novo Nordisk in 2012
31. jan. 2013 12.26 EnglishIt’s business as usual for the pharmaceutical company Novo Nordisk, which has yet again posted record sales and profit figures for its insulin products.
18 per cent growth
Novo Nordisk emerged from 2012 with a record pre-tax profit of DKK 27.8 billion. In 2011, its profit was DKK 21.9 billion, so its bottom line grew by 18 per cent.
Sales also boomed, totalling more than DKK 78 billion in 2012, an increase of 18 per cent on the previous year.
And there is nothing to suggest that this year will be any different.
Share price soaring
On 23 January, the Novo Nordisk share topped the magic mark of DKK 1,000, and the Group’s market value is estimated at around DKK 560 billion.
Furthermore, last year the company obtained approval for the long-acting insulin Tresiba® and the insulin combination Ryzodeg® in both Europe and Japan, while it is currently awaiting approval from the American authorities. These products will further boost the company’s bottom-line growth.
For 2013, Novo Nordisk forecasts that overall sales will grow by 8-10 per cent.